FDA approves Cytokinetics’ MYQORZO for obstructive HCM after SEQUOIA-HCM trial success

The United States Food and Drug Administration has approved aficamten, now branded as MYQORZO, developed by Cytokinetics, Incorporated, for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy. The oral cardiac myosin inhibitor is the company’s first approved medicine and is expected to launch in the U.S. in January 2026 under a restricted distribution program.

The approval provides an alternative to mavacamten, sold as Camzyos by Bristol Myers Squibb, and positions Cytokinetics to compete in a precision cardiology market segment that has until now had limited therapeutic innovation. However, the approval arrives amid investor concerns about Cytokinetics’ balance sheet, commercialization readiness, and the burden of REMS (Risk Evaluation and Mitigation Strategy) requirements tied to the product’s boxed warning.

What does FDA approval of aficamten mean for the treatment of obstructive hypertrophic cardiomyopathy?

Aficamten is an oral, selective cardiac myosin inhibitor designed to reduce hypercontractility in patients with symptomatic obstructive hypertrophic cardiomyopathy. The condition, which results from abnormal thickening of the heart muscle and obstruction of blood flow from the left ventricle, can cause symptoms including chest pain, dyspnea, syncope, and sudden cardiac death.

The FDA approval is based on results from the Phase 3 SEQUOIA-HCM trial, which demonstrated that aficamten significantly improved functional capacity and reduced symptoms compared to placebo. Patients receiving aficamten achieved greater improvement in peak oxygen uptake (pVO₂) and New York Heart Association (NYHA) functional class, along with improved scores on health-related quality-of-life assessments.

This regulatory milestone gives physicians a new option for managing a chronic, often progressive cardiac condition for which beta-blockers, calcium channel blockers, and surgical septal myectomy have remained longstanding but imperfect solutions. With aficamten’s approval, treatment can now be personalized based on a mechanistic understanding of sarcomere hypercontractility, rather than relying solely on symptom relief or structural interventions.

How does MYQORZO compare with Camzyos from Bristol Myers Squibb?

Camzyos, the first cardiac myosin inhibitor approved for obstructive hypertrophic cardiomyopathy, has already established a commercial footprint in the United States and key European markets. Aficamten’s entry sets the stage for a direct head-to-head comparison, both in clinical outcomes and in how cardiologists balance efficacy, safety, and convenience.

One key differentiator is aficamten’s shorter half-life, which allows more rapid titration and potentially easier management of adverse events. Cytokinetics has emphasized aficamten’s pharmacokinetic profile as a potential safety and dosing advantage. However, MYQORZO carries the same class effect risks as Camzyos, particularly the possibility of systolic dysfunction due to over-suppression of myocardial contractility.

Cytokinetics’ product label includes a boxed warning for heart failure due to left ventricular ejection fraction (LVEF) reduction, echoing that of Camzyos. Like its rival, MYQORZO requires echocardiographic monitoring and enrollment in a REMS program to ensure safe use. Therefore, while differentiation exists, the two drugs share many regulatory, clinical, and commercial constraints.

The battle for market share may come down to subtle distinctions in safety margin, physician familiarity, payer coverage, and the speed with which Cytokinetics can build commercial infrastructure to match that of Bristol Myers Squibb.

What are the REMS requirements and boxed warnings associated with aficamten?

The MYQORZO prescribing label includes a boxed warning for the risk of heart failure due to LVEF reduction. As a result, aficamten will be distributed under a REMS program that mandates baseline and ongoing echocardiography to monitor ejection fraction. This imposes a logistical burden on both prescribers and patients, and could limit uptake to specialized centers familiar with managing myosin inhibition.

Patients initiating MYQORZO therapy must have an LVEF of at least 55 percent. Regular echocardiographic monitoring is required during titration and maintenance therapy, and clinicians must adjust dosing or interrupt therapy based on LVEF trends. These requirements mirror those of Camzyos and reflect a broader class effect concern associated with cardiac myosin inhibitors.

Although the REMS protocol is a known hurdle in commercial cardiology, the infrastructure is now more established following Camzyos’ rollout. That may reduce friction for aficamten’s adoption, but only if Cytokinetics can execute a coordinated launch strategy with specialty pharmacies, diagnostic labs, and echo-capable clinics.

Can Cytokinetics turn MYQORZO into a commercial success amid financial headwinds?

While the approval is a milestone for Cytokinetics, it comes at a time when the company is facing mounting pressure to deliver commercial results. MYQORZO is the company’s first approved therapy after years of R&D spending and a failed attempt to bring its earlier heart failure candidate, omecamtiv mecarbil, to market.

Cytokinetics ended Q3 2025 with approximately $500 million in cash, cash equivalents, and marketable securities. However, the cost of launching a cardiology product with REMS requirements, especially against an entrenched competitor like Bristol Myers Squibb, will strain resources. The company has not yet secured a major commercialization partner for aficamten and may need to raise additional capital or consider strategic options if early revenue uptake is slow.

Analysts have also flagged that Cytokinetics has multiple ongoing trials evaluating aficamten in broader HCM and non-obstructive populations, which could expand the market but require additional investment and regulatory risk tolerance.

The company’s stock (NASDAQ: CYTK) traded modestly higher after the FDA announcement, reflecting investor relief rather than exuberance. The muted reaction suggests that Wall Street is waiting for evidence of execution—particularly formulary wins, physician adoption metrics, and early sales trends—before repricing the long-term opportunity.

How does aficamten reshape the cardiac myosin inhibitor landscape?

The approval of a second cardiac myosin inhibitor within three years confirms the viability of this drug class and strengthens the shift toward mechanistically targeted therapies in cardiomyopathies. Aficamten’s differentiated pharmacologic profile, including a faster onset and offset, may influence future drug design even beyond HCM, into heart failure with preserved ejection fraction (HFpEF) and other structural heart diseases.

Cytokinetics is currently evaluating aficamten in additional trials, including REDWOOD-HCM and FOREST-HCM, aimed at expanding its indication base. The company has also initiated trials in non-obstructive HCM, a condition with even fewer approved therapies.

More broadly, aficamten’s approval validates the strategy of targeting sarcomere hypercontractility rather than relying solely on heart rate reduction or mechanical relief. If outcomes and safety remain favorable in real-world use, this class could eventually expand to earlier-stage patients or be integrated into guideline-directed therapy alongside existing agents.

The longer-term implications may also include shifts in diagnostic protocols, with earlier genetic and echocardiographic screening to identify candidates eligible for myosin inhibition before disease progression requires invasive interventions.

What are the key takeaways from aficamten’s FDA approval and market entry strategy?

• Cytokinetics, Incorporated received FDA approval for aficamten, branded as MYQORZO, for treating symptomatic obstructive hypertrophic cardiomyopathy.

• The drug is a cardiac myosin inhibitor that works by reducing left ventricular contractility in patients with sarcomere hyperactivity.

• MYQORZO’s approval was based on Phase 3 SEQUOIA-HCM results and includes a boxed warning for potential heart failure, necessitating REMS enrollment.

• The therapy competes directly with Bristol Myers Squibb’s Camzyos, which is already established in the oHCM market with a similar safety and monitoring profile.

• Aficamten’s faster pharmacokinetics may offer clinical advantages, but uptake will depend on Cytokinetics’ ability to scale REMS infrastructure and secure payer access.

• The company faces capital pressure and must navigate commercialization without a major partner while continuing trials for label expansion.

• The approval solidifies cardiac myosin inhibitors as a therapeutic class and may drive earlier diagnosis and treatment in cardiomyopathy care pathways.

• Institutional investors remain cautiously optimistic, awaiting execution signals before assigning full commercial credit to aficamten.